Abstract
Background We deal with genetic complexity through population structure to reduce the number of markers, condition case/control study results and combat the confounding influence of genetic heterogeneity and minor locus effects. This abstract describes the screening of patient genomes to construct a DNA based test for measuring Taxol/Carboplatin response proclivities. Methods Pan genome maps of Ancestry Informative Markers to estimate individual biogeographical ancestry admixture for patient samples, integrated with a case/control design were used to screen the genome. Results Taxol/Carboplatin response was associated with Haplotypes in 3 xenobiotic metabolism genes and a few other SNPs. Integrating ancestry and gene-specific features enabled construction of a classification method for predicting Taxol/Carboplatin response proclivities that is capable of relatively sensitive, specific and powerful performance in “blind” sample classification trials. Conclusions When gene haplotype and SNP associations are viewed through the lens of biogeographical ancestry admixture, pattern emerges that enables relatively accurate classification of patient response proclivities to Taxol/Carboplatin in ovarian cancer patients. Clinical Pharmacology & Therapeutics (2005) 77, P61–P61; doi: 10.1016/j.clpt.2004.12.124
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
